Geron Corporation (GERN NASDAQ) stock market data APIs
$1.3742
0(0%)
as of January 30, 2026
Try our APIs with
free plan!
Geron Corporation Financial Data Overview
Price chart is built with
Anychart
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. It offers RYTELO a telomerase inhibitor for the treatment f adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia. The company was incorporated in 1990 and is headquartered in Foster City, California.
Prev. Close
1.3742
Open
1.376
High
1.4072
Low
1.3255
52 wk Range
1.04-3.09
Market Cap
875 M
Shares Outstanding
638 M
Revenue
183 M
EPS
-0.03
Beta
0.593
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Geron Corporation (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Geron Corporation data using free add-ons & libraries
Get Geron Corporation Fundamental Data
Geron Corporation Fundamental data includes:
- Net Revenue: 183 M
- EBITDA: -62 566 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-06
- EPS/Forecast: -0.0256
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Geron Corporation News
New
Geron Corporation (GERN) Eyes Profitability in 2026 amid Restructuring Drive
Geron Corporation (NASDAQ:GERN) is one of the best debt-free penny stocks to buy right now. On January 12, Geron Corporation (NASDAQ:GERN) announced its 2026 outlook, forecasting $220–240 million in...
Geron Corporation (GERN) Streamlines Operations, Secures Financing, Eyes 2026 Growth
Geron Corporation (NASDAQ:GERN) is one of the best penny stocks to buy for 2026. On January 6, Geron Corporation (NASDAQ:GERN) amended its loan agreement with Biopharma Credit Investments and BPCR Lim...
Geron Expects Rytelo Net Sales Of $220 Mln-$240 Mln In 2026
(RTTNews) - Geron Corporation (GERN) on Monday provided financial guidance for 2026, expecting net product revenue for Rytelo in the range of $220 million to $240 million. The company said its 2026 o...
Geron (GERN) Plans Restructuring to Cut Costs, H.C. Wainwright Stays Neutral
Geron Corporation (NASDAQ:GERN) is one of the 10 Best US Penny Stocks to Buy. On December 11, H.C. Wainwright maintained its Neutral rating on Geron Corporation (NASDAQ:GERN) after the company announc...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
